Pulnovo Medical Secures $100M Series C Financing

Pulnovo Medical has successfully closed an oversubscribed Series C funding round, raising nearly $100 million to further its global clinical trials and business expansion in the medical device sector. The financing round, co-led by Qiming Venture Partners and existing shareholder Lilly Asia Ventures, has attracted significant interest from institutional investors, oversubscribing by two times. Founded in 2013, Pulnovo specializes in developing therapeutic solutions for pulmonary hypertension (PH) and heart failure, with its core product, Pulmonary Artery Denervation (PADN) technology, receiving FDA Breakthrough Device designation. The funds will support upcoming FDA trials for PH-related conditions, reflecting confidence in Pulnovo's strategic direction and technological capabilities. PADN is noted for its minimally invasive approach, targeting pulmonary vascular nerves to reduce disease progression. The company has established a global presence, with market approvals for its devices in China and ongoing trials in multiple international locations.